Eliford Ngaimisi

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations

Eliford Ngaimisi, Abiy Habtewold, Omary Minzi et al. · PLoS ONE · 2013 · 124 citations · Full text

Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

Eliford Ngaimisi, Sabina Mugusi, Omary Minzi et al. · Clinical Pharmacology & Therapeutics · 2010 · 105 citations

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

Eliford Ngaimisi, Sabina Mugusi, Omary Minzi et al. · Clinical Pharmacology & Therapeutics · 2011 · 81 citations

Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania

Sabina Mugusi, Eliford Ngaimisi, Mohamed Janabi et al. · PLoS ONE · 2012 · 60 citations · Full text

CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients

Betty A. Maganda, Omary Minzi, Eliford Ngaimisi et al. · The Pharmacogenomics Journal · 2015 · 49 citations

Medicine, Malaria, Antiviral Drug Development +8